Skip to main content

Table 1 Treatment schedule for the frequency of gefitinib and NKT cell in both arms of the trail

From: A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

Week-4-0 Week
0–8
One cell therapy cycle
Week
9–12
Week 13–16 Week
17–20
Week
21–24
Week
25–28
Screening Randomization Experimental group (Arm A) Donor selection, PBMCsa acquisition and NKT cell preparation NKT infusion NKT infusion NKT infusion NKT infusion Suspend
Gefitinib orally once daily
Control group (Arm B) Gefitinib orally once daily
  1. This schedule use one cell therapy cycle as an example, and the follow-up treatment is carried out according to the same cell therapy cycle until the trial is terminated after the disease has progressed or complete three cell therapy cycles (total 60 weeks). aPBMCs peripheral blood mononuclear cells